SORRENTO THERAPEUTICS, INC. Form 8-K (March 3, 2022)

Summary

Current report on Form 8-K for an event dated March 3, 2022, filed by Sorrento Therapeutics, Inc. Under Item 8.01, the report states that on March 3, 2022 the company filed a prospectus supplement to the prospectus dated December 23, 2021 for the purpose of registering the resale of up to 1,281,662 shares of the company's common stock by the selling stockholders identified therein. The company will not receive any proceeds from the sale of those shares. The report provides the legal opinion on the validity of the shares, attached as Exhibit 5.1 (Opinion of Paul Hastings LLP). Henry Ji signed on March 3, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): March 3, 2022

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On March 3, 2022, Sorrento Therapeutics,
Inc. (the “Company”) filed with the Securities and Exchange Commission (the “Commission”) a prospectus
supplement (the “Prospectus Supplement”) to the prospectus dated December 23, 2021 included in the Company’s
automatic shelf registration statement on Form S-3ASR (File No. 333-261888). The Prospectus Supplement was filed for the purpose of
registering the resale of up to 1,281,662 shares of the Company’s common stock, par value $0.0001 per share (the "Shares"), from time to
time by the selling stockholders identified therein. The Company will not receive any proceeds from the sale of the Shares by the
selling stockholders.

The Company is filing this report to provide the legal opinion as to the validity of the Shares covered by the Prospectus Supplement,
which opinion is attached hereto as Exhibit 5.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

5.1 | Opinion of Paul Hastings LLP.
23.1 | Consent of Paul Hastings LLP (included in Exhibit 5.1) .
104 | Cover Page interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: March 3, 2022 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman, President and Chief Executive Officer

File and source

File

SEC_SRNE_8-K_filed2022-03-03_0001104659-22-030103.htm

Size

24,768 bytes

SHA-256

edbfa1c69739997173ff1fd9b8fb1a69b7e4c9cbdd1fe3bc5263e61a7dd7ef19

Our copy

SEC_SRNE_8-K_filed2022-03-03_0001104659-22-030103.htm

Original

www.sec.gov